Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC)
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Surgical Wound Infection
Conditions
Surgical Wound Infection, Traumatic Wound Infection
Trial Timeline
Feb 2, 2026 → Oct 28, 2026
NCT ID
NCT07379684About Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC)
Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC) is a phase 1 stage product being developed by Novo Nordisk for Surgical Wound Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07379684. Target conditions include Surgical Wound Infection, Traumatic Wound Infection.
What happened to similar drugs?
7 of 20 similar drugs in Surgical Wound Infection were approved
Approved (7) Terminated (5) Active (10)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07379684 | Phase 1 | Recruiting |
Competing Products
20 competing products in Surgical Wound Infection